Alpelisib (BYL719)

Catalog No.S2814

For research use only.

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Alpelisib (BYL719) Chemical Structure

CAS No. 1217486-61-7

Selleck's Alpelisib (BYL719) has been cited by 150 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Other PI3K Products

Biological Activity

Description Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.
Targets
PI3Kα [1]
(Cell-free assay)
5 nM
In vitro

BYL719 inhibits the proliferation of breast cancer cell lines harboring PIK3CA mutations, correlating with inhibition of various downstream signaling components of the PI3K/Akt pathway. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Detroit562 MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[wMlEuOTByIN88US=> MYq3NkBp MXzJR|UxRTFwMUCg{txO MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3MEW0PUc,OjV3NUC1OFk9N2F-
SNU-1076 M2D0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf6ZoExNjFvMUCwJO69VQ>? NXTmfINjPzJiaB?= MUTJR|UxRTZwOEKg{txO M{nIdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUWwOVQ6Lz5{NUW1NFU1QTxxYU6=
SNU-1066 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LmT|AvOS1zMECg{txO NXLxc2ttPzJiaB?= NHXTVVFKSzVyPUGuNVMh|ryP NHXSTVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1NFU1QSd-MkW1OVA2PDl:L3G+
FaDu MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLyXYFQOC5zLUGwNEDPxE1? M3TLTFczKGh? NHnITGFKSzVyPUG5MlY3KM7:TR?= NFiwcGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1NFU1QSd-MkW1OVA2PDl:L3G+
SNU1041 M{npOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLyNE4yNTFyMDFOwG0> MV63NkBp M4TUWWlEPTB;MkCuOlUh|ryP NWHMbmw2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVA2PDlpPkK1OVUxPTR7PD;hQi=>
SCC25 NFv0UZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVqwMlEuOTByIN88US=> NVnpdJhjPzJiaB?= M1vVWWlEPTB;NEmuN|Ah|ryP M2HITVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUWwOVQ6Lz5{NUW1NFU1QTxxYU6=
BON-1 MkLUSpVv[3Srb36gRZN{[Xl? MYKxM|ExKM7:TR?= MWi0JIg> NVvoe5pbcW6qaXLpeJMhWEl|SzCoRWtVKFOnckOwPEkh[W6mIH3UU3JEOS9{IHHjeIl3cXSrZYO= NHX6ZnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyOlI6Oid-MkWwNlYzQTJ:L3G+
QGP-1 MnvxSpVv[3Srb36gRZN{[Xl? NITzTWkyNzFyIN88US=> MnG5OEBp NHz0eXBqdmirYnn0d{BRUTONIDjBT3QhW2W{M{C4LUBidmRibWTPVmMyNzJiYXP0bZZqfGmncx?= M37h[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK2NlkzLz5{NUCyOlI6OjxxYU6=
MG-63 MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnPVWZKSzVyPU[g{txO97zOIFnDPVA:OjRizszN Ml;jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NkG3PVAoRjJ2OU[xO|kxRC:jPh?=
HOS MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF3IN88Ug+9lCCLQ{mwQVQzKM7:TR?= NEHGVIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm2NVc6OCd-MkS5OlE4QTB:L3G+
MOS-J M4X2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;KeYVKSzVyPUGwJO69Ve,:jDDJR|kxRTN4IN88US=> M{HEOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OU[xO|kxLz5{NEm2NVc6ODxxYU6=
POS-1 NH3wNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HrcmlEPTB;ODFOwG3wxIxiSVO5NF0{PiEQvF2= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl4MUe5NEc,OjR7NkG3PVA9N2F-
92.1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF22U4c2ODBvMkCwNEBvVQ>? NYDqO|dkPSCm MXvpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd|KTD1dEB1dyBzIN88US=> NGXofmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2N|U1OCd-MkS1OlM2PDB:L3G+
Mel270 Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr0e|U2ODBvMkCwNEBvVQ>? NYfUc5Q{PSCm NF3Qb5lqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWEApW2W{NEezLUB2eCC2bzCxJO69VQ>? MoXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NkO1OFAoRjJ2NU[zOVQxRC:jPh?=
Omm1.3 NGTUZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL4W|R7PTByLUKwNFAhdk1? MoTYOUBl Mk\zbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2SgLHNmejR5MzmgeZAhfG9iMTFOwG0> M{DxWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[zOVQxLz5{NEW2N|U1ODxxYU6=
Omm1 MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PadFUxOC1{MECwJI5O MlvEOUBl NXToUmlFcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBT3QhMFOnckS3N{khfXBidH:gNUDPxE1? M{T0SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[zOVQxLz5{NEW2N|U1ODxxYU6=
C918 NXfpRW5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjaToo2ODBvMkCwNEBvVQ>? M3P4[VUh\A>? NFrwS|dqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWEApW2W{NEezLUB2eCC2bzCxJO69VQ>? NW\sd2R{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlM2PDBpPkK0OVY{PTRyPD;hQi=>
Mel290 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[1NFAuOjByMDDuUS=> M1Lre|Uh\A>? NX;ne5pCcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBT3QhMFOnckS3N{khfXBidH:gNUDPxE1? NFTPZpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2N|U1OCd-MkS1OlM2PDB:L3G+
OPM2 NHrCeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPGNE42NTJwNTFOwG0> MXy0PEBp MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHXYfoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwOVEzOSd-MkS0NFUyOjF:L3G+
OPM1 M3foR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC2NYNoOC53LUKuOUDPxE1? M4LI[FQ5KGh? NVzK[Zh2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXnoVWhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFUyOjFpPkK0OFA2OTJzPD;hQi=>
U266 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS4NE42NTJwNTFOwG0> M1rrT|Q5KGh? MWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyNUGyNUc,OjR2MEWxNlE9N2F-
MM1R NW[5SW5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnG[4o{OC53LUKuOUDPxE1? NFHrOXo1QCCq NUPNfnl4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{nWXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEC1NVIyLz5{NESwOVEzOTxxYU6=
MM1S MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDaVmkxNjVvMj61JO69VQ>? NXrON|lGPDhiaB?= NILFNm9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4LocFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEC1NVIyLz5{NESwOVEzOTxxYU6=
H929 NFS1S4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmwMlUuOi53IN88US=> MWC0PEBp NUPKRpVJcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn;sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEWxNlEoRjJ2NEC1NVIyRC:jPh?=
RPMI MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PJdFAvPS1{LkWg{txO MX60PEBp MWjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mn7lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEWxNlEoRjJ2NEC1NVIyRC:jPh?=
SKBR3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[zN{DPxE1? NXvZeGdWPSCm NILN[pRqdmirYnn0d{A{Pe,:hTDj[YxtKGe{b4f0bC=> MoiwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
MDA453 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTPN|Mh|ryP M3rNcFUh\A>? NYHkPItncW6qaXLpeJMhOzkxvJWgZ4VtdCCpcn;3eIg> NFSwTIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
EFM192A NWHlWplPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGzN{DPxE1? M{S0OFUh\A>? MVrpcohq[mm2czCyO-+9jSClZXzsJIdzd3e2aB?= NHezSnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
AU565 M2jpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXpcpY{OyEQvF2= MUW1JIQ> NUTMR|BlcW6qaXLpeJMhOjcxvJWgZ4VtdCCpcn;3eIg> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
MDA361 M{\lPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnhcG8{OyEQvF2= NHnR[FA2KGR? M1\5W4lvcGmkaYTzJFQ197zHIHPlcIwh\3Kxd4To M2\3cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
BT474 M3PpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmzN{DPxE1? M4fCWlUh\A>? NFX6XJBqdmirYnn0d{AyPu,:hTDj[YxtKGe{b4f0bC=> M1fHOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
HCC202 Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf3N|Mh|ryP NW\rfmROPSCm M2LQeYlvcGmkaYTzJFIx97zHIHPlcIwh\3Kxd4To NYX6UJVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
KPL4 NXvlU29WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fpNFM{KM7:TR?= Mn;BOUBl M3u0[olvcGmkaYTzJFU597zHIHPlcIwh\3Kxd4To NHjzcmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
NCL-N87 NEHkNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT4[|k{OyEQvF2= M1WwfFUh\A>? M1zre4lvcGmkaYTzJFMy97zHIHPlcIwh\3Kxd4To NHvBW3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
UACC812 NWD3SIRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WyWVM{KM7:TR?= NWixVZN1PSCm NEfuV3BqdmirYnn0d{AzP+,:hTDj[YxtKGe{b4f0bC=> M2nZb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
HCC2218 M13YdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{joZ|M{KM7:TR?= MUK1JIQ> M4G2XYlvcGmkaYTzJFE297zHIHPlcIwh\3Kxd4To Mkj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
HCC1569 M3vNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVGxUpFUOzNizszN MnHqOUBl MnO4bY5pcWKrdIOgOg+9jSClZXzsJIdzd3e2aB?= MnLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
OE19 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSzN{DPxE1? MmfsOUBl M1T2PIlvcGmkaYTzJFI{97zHIHPlcIwh\3Kxd4To NXfSe4t5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
OE33 M4TsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPwTWs{OyEQvF2= NIW2O442KGR? MoTvbY5pcWKrdIOgNlPwxIViY3XscEBoem:5dHi= NHO5OZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
JIMT1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC1N|Mh|ryP MWS1JIQ> M1XqOYlvcGmkaYTzJFnwxIViY3XscEBoem:5dHi= NY\IcWtURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
HCC1954 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGzN{DPxE1? MUK1JIQ> MX\pcohq[mm2czCyPg+9jSClZXzsJIdzd3e2aB?= NUTGe4psRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
NUGC4 NYDF[HJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TwRlM{KM7:TR?= MVi1JIQ> NVTKVWpwcW6qaXLpeJMhOTUxvJWgZ4VtdCCpcn;3eIg> M320WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
ZR-75-30 MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M336eVM{KM7:TR?= MVm1JIQ> NXfN[pNqcW6qaXLpeJMhNTF378{FJINmdGxiZ4Lve5Rp M1;lNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
Rat1 MWfQNVEx[WyyaHGgbY5pcWKrdHnvckBie3OjeR?= NX;nO4dVUUN3MDC9JFAvODd2IN88US=> M2PmNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MU[0NVg6Lz5{NkG2OFE5QTxxYU6=
Rat1 NVqwTXdbWEl|S3HsdIhiKGmwaHnibZRqd25iYYPzZZk> NUXzVWJTUUN3MDC9JFAvODd2IN88US=> MmLnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{ME[1NFQoRjJ4MkC2OVA1RC:jPh?=
Rat1 M1zhSnAyOTCjbIDoZUBqdmirYnn0bY9vKGG|c3H5 NU\aPZE{UUN3MDC9JFAvODd2IN88US=> NGG1S|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyOlA{PCd-MkO3NlYxOzR:L3G+
Rat1 NYPubXlRWDFzMHTlcJRiKGmwaHnibZRqd25iYYPzZZk> MoLpTWM2OCB;IEGuNkDPxE1? NG\VNWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2OFE5QSd-Mk[xOlQyQDl:L3G+
Rat1 MYjQTVNM\2GvbXGgbY5pcWKrdHnvckBie3OjeR?= MoD0TWM2OCB;IEGuNkDPxE1? MoDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{ME[1NFQoRjJ4MkC2OVA1RC:jPh?=
Rat1 MmD3VFEyOGSnbIThJIlvcGmkaYTpc44h[XO|YYm= M{LoTWlEPTBiPTCxMlIh|ryP MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{NkCzOEc,OjN5Mk[wN|Q9N2F-
Rat1 MVLQNVEx[mW2YTDpcohq[mm2aX;uJIF{e2G7 MnnvTWM2OCB;IEKuNkDPxE1? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4NEG4PUc,OjZzNkSxPFk9N2F-
Rat1 NGDBUHVRUTONYnX0ZUBqdmirYnn0bY9vKGG|c3H5 Mnf1TWM2OCB;IEKuNkDPxE1? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJyNkWwOEc,OjZ{ME[1NFQ9N2F-
Rat1 MYrQNVEx[WyyaHGgbY5pcWKrdHnvckBie3OjeR?= M{j3RWlEPTBiPTCyMlIh|ryP MnrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mk[wN|QoRjJ|N{K2NFM1RC:jPh?=
Assay
Methods Test Index PMID
Western blot p-AKT(S473) / p-AKT(T308) ; p100β / p110α / p85 / p-ERBB3(Y1289) ; p-HER2 / IGF-1R ; pS6 (Ser235-236) ; PIM1 / PIM2 / PIM3 / p-PRAS40 / p-RPS6 / p-BAD 25544637 27048245 27604488
Growth inhibition assay Cell viability 27602501
Immunofluorescence LC3 26637440
In vivo BYL719(>270 mg/d) shows statistically significant dose-dependent anti-tumor efficacy in PIK3CA mutant xenograft models in rodents. BYL719 has a low clearance, a half-life of 8.5 h and its exposure increases dose proportionally between 30mg/d and 450mg/d, displaying a low inter-individual variability in Cmax and AUC in human. BYL719(270mg/d) shows first signs of clinical efficacy include 1 confirmed partial response in a patient with ER+ breast cancer, and significant PET responses (PMR) and/or tumor shrinkage are achieved in 8 out of 17 evaluated patients. [1]

Protocol (from reference)

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.

4.4 mg/mL

Chemical Information

Molecular Weight 441.47
Formula

C19H22F3N5O2S

CAS No. 1217486-61-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05143229 Not yet recruiting Drug: Alpelisib|Drug: Sacituzumab govitecan Breast Cancer University of Kansas Medical Center|Novartis Pharmaceuticals|Gilead Sciences January 2022 Phase 1
NCT04997902 Recruiting Drug: Tipifarnib|Drug: Alpelisib HNSCC Kura Oncology Inc. December 7 2021 Phase 1|Phase 2
NCT04980833 Not yet recruiting Drug: Alpelisib PIK3CA-related Overgrowth Spectrum (PROS) Novartis Pharmaceuticals|Novartis December 15 2021 Phase 2
NCT05022342 Recruiting Other: alpelisib plus fulvestrant Breast Cancer Novartis Pharmaceuticals|Novartis October 27 2021 --

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Alpelisib (BYL719) | Alpelisib (BYL719) supplier | purchase Alpelisib (BYL719) | Alpelisib (BYL719) cost | Alpelisib (BYL719) manufacturer | order Alpelisib (BYL719) | Alpelisib (BYL719) distributor